Prasad
Favicon Fierce Biotech

CBER Director Vinay Prasad to depart FDA—again

Prasad has drawn increased criticism throughout his tenure, especially from the rare disease community.
Darren Incorvaia Mar 6, 2026 5:30pm
Food and Drug Administration

Regulatory tracker: Daiichi, AZ's Enhertu wins US priority review

Mar 9, 2026 2:10pm
Uniting for patients Helping more Americans navigate access and afford their healthcare

Uniting for patients: Navigating, accessing, and affording care

Brought to you by Patient Advocate Foundation
spruce tree pinecone

Spruce hooks a commercial chief to prep for rare disease launch

Mar 9, 2026 1:15pm
data deal handshake

Novo and Hims & Hers team up to sell branded GLP-1s, ending feud

Mar 9, 2026 11:55am
Bristol Myers Squibb

FDA expands label for BMS' Sotyktu to treat psoriatic arthritis

Mar 9, 2026 11:16am
More News

‘SNL’ pokes fun at mysteries of Amgen’s Otezla for psoriasis

Mar 9, 2026 11:05am

Novo's Indiana plant claims another victim in Incyte's PD-1

Mar 9, 2026 10:45am

Safety signals prompt Ipsen to withdraw cancer med Tazverik

Mar 9, 2026 10:07am

Lonza shakes off capsule business in $3B deal with Lone Star

Mar 6, 2026 4:00pm